The cure rate of testicular cancer exceeds 95%, but testicular cancer survivors (TCS) are at increased risk of hypogonadism (HG). It has been suggested that TCS have reduced bone mineral density (BMD), but it is unclear whether this is related to HG or a direct effect of cancer therapy. The aim of this study was to evaluate whether TCS have decreased BMD, and if BMD is related to HG and/ or the cancer treatment given. We investigated 91 TCS (mean age at diagnosis: 31 years; mean 9.3 years follow-up) and equal number of age matched controls (mean age at inclusion 40.3 years and 41.2 years, respectively). Total testosterone and LH were measured. BMD was determined using dual-energy X-ray absorptiometry (DXA). Low BMD (LBD) was defined as Z-score <À1. Compared to eugonadal TCS, both TCS with untreated HG (mean difference: À0.063 g/cm 2 ; 95% CI: À0.122; À0.004 p = 0.037) and TCS receiving androgen replacement (mean difference À0.085 g/cm 2 ; 95% CI: À0.168; À0.003; p = 0.043) presented with statistically significantly 6-8% lower hip BMD. At the spine, L1-L4, an 8% difference reached the level of statistical significance only for those with untreated HG (mean difference: À0.097 g/cm 2 ; 95% CI: À0.179; À0.014; p = 0.022). TCS with untreated HG had significantly increased OR for spine L1-L4 LBD (OR = 4.1; 95% CI: 1.3; 13; p = 0.020). The associations between the treatment given and BMD were statistically non-significant, both with and without adjustment for HG. In conclusion, TCS with HG are at increased risk of impaired bone health. Prevention of osteoporosis should be considered as an important part in future follow up of these men.
INTRODUCTION
In men with testicular germ cell cancer (TGC) the cure rate exceeds 95% (Verdecchia et al., 2007) . However, long term follow-up of TGC survivors (TCS) has revealed increased morbidity and shorter life expectancy (Kvammen et al., 2016) .
So far, looking at the causes of increased morbidity and mortality, most focus has been given to cardiovascular and metabolic diseases (Haugnes et al., 2007 (Haugnes et al., , 2008 . Bearing in mind that TCS often encounter hypogonadism (Sprauten et al., 2014) , and both chemotherapy and radiotherapy may have deleterious effects on bone health (Schmeler et al., 2010; Silbermann & Roodman, 2011) , one could expect that TGC as well as its treatment may be associated with impaired bone health.
In a prospective study of newly diagnosed TGC patients, Willemse et al. (2014) recently reported normal BMD in stage I patients, whereas those with metastatic disease given chemotherapy presented a significant decrease in BMD, unrelated to the dose cisplatin or corticosteroids given. Also the study by Foresta et al. (2013) showed lower BMD in TCS as compared to controls, despite no biochemical signs of testosterone deficiency in the patient group. Another follow-up study (Willemse et al., 2010) reported TCS to have increased prevalence of mild to moderate vertebral fractures, with no association to BMD and the treatment given whereas Murugaesu et al. (2009) found no increased risk of osteoporosis in this patient group. Finally, Ondrusova et al. recently reported 43-51% of TCS presenting with osteopenia/osteoporosis (T-/Z-score <À1). There was no increased risk of osteopoenia/osteoporosis in patients treated with unilateral orchidectomy and radiotherapy or 2-4 cycles of chemotherapy, compared to patients treated with unilateral orchidectomy alone (Ondrusova et al., 2016) .
Thus, the data on the impact of testosterone deficiency and treatment modality on BMD in TCS is rather conflicting.
Relatively small patients groups, short follow up period, lack of proper controls as well as non-standardized conditions for determination of sex hormone levels, might be some of the explanations behind these contradictory results.
In order to address some of these shortcomings, we have investigated a group of 91 TCS followed for a mean posttreatment period of 9.3 years and a cohort of age matched controls in order to assess BMD and the risk of low BMD, and also to elucidate possible associations with biochemical signs of hypogonadism as well as to the cancer treatment given.
MATERIALS AND METHODS

TCS
The study was based on a cohort of 165 TCS, aged 24-57 years, treated at Lund University Hospital between March 2001 and October 2006 and previously included in a study on reproductive function (Eberhard et al., 2008) . Three TCS were deceased and one had emigrated. Of the remaining 161 men invited for this study, positive reply was received from 97 men. Three dropped out of the study, two were excluded due to prostate cancer or prolactinoma diagnosed shortly after inclusion and one declined DXA leaving 91 (57%) subjects included.
All TCS underwent unilateral orchidectomy, and one was subsequently also contralaterally orchidectomized due to development of TGC in the remaining testicle. Extra-gonadal tumour, as primary diagnosis, was found in three TCS. Nine men were on androgen replacement therapy and one case was on oral corticosteroids after a kidney transplantation.
The distribution of TCS having 0, 1, 2 or ≥3 children was 11%, 37%, 47% and 4% among participants, and 15%, 36%, 33% and 16% among non-participants (patients excluded or unwilling to participate in current study and/or in the study performed by Eberhard et al. (2008) ).
Treatment was given according to the SWENOTECA (Swedish Norwegian Testis Cancer Group) protocols applied at time of diagnosis (March 1996 -March 2006 , (SWENOTECA 1995 (SWENOTECA -2004 . Following treatment categories (post-orchidectomy) were defined:
• surveillance only; • adjuvant chemotherapy: 1-2 cycles of cisplatin-based chemotherapy or carboplatin;
• standard chemotherapy: 3-4 cycles of cisplatin-based chemotherapy;
• adjuvant irradiation (ART) of para-aortic and ipsilateral iliac lymph nodes (treatment option to patients with stage I seminoma during 2000 -2006 (SWENOTECA 1995 -2004 . Irradiation dose was 25.2 Gray (Gy) in 14 fractions for all but one patient, who received 24 Gy in 16 fractions;
• extensive treatment with chemotherapy AE non-testicular irradiation. The number of chemotherapy cycles was 8 (n = 4) or 9 (n = 1). Among these men, one also received cranial irradiation and another also received radiotherapy to para-aortic lymph nodes;
• testicular irradiation: One patient received 1 cycle of cisplatin-based chemotherapy plus radiotherapy to the contralateral testicle due to Germ Cell Neoplasia in situ (GCNIS). He was subsequently contralaterally orchidectomized and treated with ART due to TGC in the irradiated testicle. Yet another patient received ART plus radiotherapy to the contralateral testicle due to GCNIS. The numbers of patients within the different categories and their background characteristics are given in Table 1 .
Controls
For each participating TCS in the current study, a control matched by date of birth was recruited through the Swedish Population Register. Exclusion criteria were: (i) Previous diagnosis of tumour in the CNS or a malignant disease other than basal cell carcinoma or (ii) Klinefelters syndrome (47, XXY).
We approached 389 subjects and 101 of them (26%) accepted inclusion. One subsequently dropped out of the study, one was excluded due to radiation therapy of a giant cell tumour, four were excluded due to exclusion or drop out of the corresponding TCS and four were duplicates of existing controls.
Among controls to our cohort of cancer survivors, the distribution of those having 0, 1, 2 or ≥3 children was 12%, 42%, 35% and 11% among participants, and 21%, 46%, 23% and 10% among those who refused participation or were excluded for reasons given above (data based on the national Swedish registries). Among the included controls, one had been radically operated due to basal cell carcinoma in the face and two admitted to prior use of anabolic steroids (17 and 26 years earlier, respectively).
None of the controls received androgen replacement therapy. One control was on oral corticosteroids due to ulcerative colitis.
The study was approved by the Regional Ethics Committee, Lund University and all participants received written information and signed an informed consent form.
Clinical and laboratory investigations
Patients and controls were investigated between December 2009 and August 2013. All participants completed a questionnaire on health status, medication and smoking habits. Data on fractures was not collected. Anthropometric characteristics were assessed. A stadiometer was used for height measurements to the nearest 0.1 cm and an electric scale for weight to the nearest 0.1 kg. Body Mass Index (BMI) was calculated according to the formula 'weight in kilograms divided with the squared height in metres', and expressed in kg/m 2 .
Fasting venous blood samples were drawn between 8.00 and 10.00 a.m. Serum values of total testosterone (TT), luteinising hormone (LH) and sex hormone binding globulin (SHBG) were measured. Serum values of TT were assessed by a competitive immunoassay with a luminometric technique (Access; Beckman Coulter, Chaska, MN; analytic range 0.35-55.5 nmol/L, total coefficient of variation (CV) ranging from ≤20% at 1.74 nmol/L to <10% at 6.9-34.7 nmol/L). Reference range 10-35 nmol/L. LH was determined with a two-step immunometric assay with a luminometric technique (Access; Beckman Coulter; analytic range 0.2-250 IU/L, total CV <10%). Reference range 1.0-10 IU/L. SHBG was analysed with a solid-phase, two-site chemiluminescent immunometric assay (Immunolite 2000; Siemens Healthcare, United Kingdom; total CV <7%). Reference range 13-90 nmol/L.
In May 2012, methods of analysis were changed to a one-step immunometric sandwich assay with ElectroChemiLuminiscenceImmunoassay (ECLI) detection technique (Cobas, Roche, Basel, Switzerland) for SHBG and LH, and to a two-step competition assay with ECLI detection technique for testosterone (Cobas, Roche, Basel, Switzerland). To enable transformation of serum values, hormonal values were re-analysed with the new method from frozen sera in 124 men, in which we had carried out hormonal analyses using the previous methods. Hence, we made an internal validation comparing both methods. From the linear curve of best fit we obtained factors for mathematical conversion of old values to approximations of new values. Transformations were done for 5 TCS and 37 controls.
Bone mineral density
Bone mineral density (g/cm²) at the femoral neck (FN), total hip (TH) and lumbar spine L1-L4 was measured. BMD was assessed using dual-energy X-ray absorptiometry (DXA); Lunar Prodigy (GE Healthcare Lunar, Madison, WI, USA), software versions 2.15-7.70 for the majority of participants. In one TCS and 28 controls, instrument failure obliged us to use the Lunar iDEXA (GE Healthcare Lunar, Madison, WI, USA). The BMD data used in the statistical analyses have been adjusted to the Prodigy. To do this, a cross-calibration was performed using 34 healthy individuals, who underwent DXA scans by both devices. Using a Bland & Altman plot the mean difference in BMD was calculated (0.0006 g/cm 2 at FN; 0.0002 g/cm 2 at TH; À0.0088 g/cm 2 at L1-L4) and subsequently added to the original value. We found no inherent bias and a very good correspondence between measurements made by the two devices. DXA measurements were performed by the same research technicians throughout the study period, and stability and accuracy were monitored using a manufacturer-supplied phantom three times per week. The precision coefficients (CV %) for DXA have been reported previously as 0.9% FN, 0.5% TH and 0.7% L1-L4 (Callreus et al., 2014) . Z-scores, a comparison of an individual's bone density with that of a healthy reference population (NHANES III) of the same sex, age and weight and expressed as standard deviations, were obtained from the machine. In this study, low bone density was defined as a Z-score <À1.0 because of the relatively low age of the subjects.
Definition of hypogonadism
Hypogonadism was defined as TT < 10 nmol/L and/or LH>10 IU/L, or ongoing androgen replacement therapy (Nieschlag et al., 2004) .
Statistical analysis
Categorical variables are expressed as number and percentage, and continuous variables as mean with standard deviation (SD).
Applying unilateral regression models, following analyses of BMD at TH and L1-4 were done:
• All TCS vs. controls;
• Hypogonadal TCS (all; receiving and not receiving androgen replacement separately) vs. eugonadal TCS;
• Different TGC therapy subgroups, as defined above, vs. controls. The two patients receiving testicular irradiation were excluded from this analysis due to small subgroup size. The results are presented as mean difference with 95% confidence interval (95% CI). The total numbers may vary slightly because of exclusion of two patients (testicular irradiation due to Germ Cell Neoplasia in situ) not belonging to any of the major treatment categories.
b All patients, except one patient with stage III disease at diagnosis, had relapsing disease. Regression analysis of absolute BMD values and Z-scores was performed and data adjusted for age, BMI and current smoking. Subsequently, same analysis was done following exclusion of subjects on androgen replacement or oral corticosteroids in analysis A, and adjustment for treated or untreated hypogonadism in analysis C. Analysis C was then repeated with adjustment for total testosterone instead of treated or untreated hypogonadism. Untransformed DXA parameters were used as independent variables since the distribution of residuals in linear regression models did not deviate from normal distribution. Using binary logistic regression, we calculated odds ratio (OR) for low BMD.
Since the field of irradiation of retroperitoneal lymph nodes given to TGC patients is asymmetric, there is a side difference regarding the irradiation dose given to the two hips. In order to explore the possible local effect on bone density, the BMD and the Z-scores for the irradiated and the non-irradiated hip were compared using the Wilcoxon test for paired data.
All statistical analyses were performed using SPSS version 20.0 software (SPSS Inc., Chicago, IL, USA), and p-values <0.05 were considered statistically significant.
RESULTS
Characteristics of TCS, including subgroups by treatment, and controls are shown in Table 1 . In general all TCS, with exception of those given 3-4 cycles chemotherapy, presented with higher mean BMI than the control group. TCS also had a higher number of smokers than the control group (Table 1) . Five TCS and no controls presented with high LH only.
TCS vs. controls
TCS presented with a statistically non-significantly lower BMD than controls at the total hip (mean difference: À0.027 g/cm 2 ; 95% CI: À0.062; 0.009 g/cm 2 ; p = 0.14), whereas for L1-L4, a reciprocal difference was seen (mean difference: 0.027 g/cm 2 ;
95% CI: À0.021; 0.075 g/cm 2 ; p = 0.27) ( Table 2 ). These estimates were robust for exclusion of men being on oral corticosteroids or androgen replacement therapy.
For total hip, the OR for low BMD was statistically non-significantly higher among the patients (OR = 1.6; 95% CI: 0.69; 3.8; p = 0.27) and lower for L1-L4 (OR = 0.66; 95% CI: 0.31; 1.3; p = 0.22), those figures being roughly unchanged after exclusion of men being on oral corticosteroids or androgen replacement therapy. ; p = 0.043) presented with statistically significantly 6-8% lower hip BMD (Table 3) . For the spine L1-L4, an 8% difference was reaching the level of statistical significance only for those with non-treated hypogonadism (mean difference: À0.097 g/cm 2 ; 95% CI: À0.179; À0.014 g/cm 2 ; p = 0.022). Corresponding to these findings, the OR for low BMD of the hip was increased for both groups of hypogonadal men (treated and untreated), but only for the latter subgroup reached borderline statistical significance (OR = 3.7; 95% CI: 1.0; 14; p = 0.050). The number and proportions of men with hip low BMD among eugonadal, untreated hypogonadal and those given androgen replacement were n = 7 (13%), n = 6 (27%) and n = 2 (22%), respectively. Hypogonadal untreated TCS presented significantly increased OR for spine L1-L4 low BMD (OR = 4.1; 95% CI: 1.3; 13; p = 0.020) (Figure 1 ). The number and proportions of men with spine low BMD were n = 8 (14%), n = 9 (41%) and n = 2 (22%) for eugonadal, untreated hypogonadal and those given androgen replacement, respectively.
Hypogonadal vs. eugonadal TCS
The results were unchanged when adjusting for total testosterone instead of +/-hypogonadism (data not shown).
Treatment modalities
Compared to controls, for TCS having received 3-4 cycles of chemotherapy or >4 cycles of chemotherapy, the reduction of hip BMD was close to the level of statistical significance (p = 0.066 and p = 0.070, respectively) ( Table 4 ). These borderline statistical significances did not persist after adjusting for hypogonadism.
The odds ratios for low BMD were not statistically significantly different for any of the treatment categories, before and after adjustment for hypogonadism.
Absolute BMD and Z-scores of hip did not differ between the irradiated and the non-irradiated hip (both p-values: 0.37; data not shown).
DISCUSSION
The most important finding from this study is that BMD among TCS, as a group, does not differ significantly from age matched controls. However, among hypogonadal TCS, BMD was significantly lower both at the hip and lower spine; for the latter site, also evident as a higher risk (OR) of low BMD, that is, less than minus one standard deviation. This pattern was most clearly seen for those with untreated hypogonadism. When measured at the hip, even patients on androgen replacement therapy presented with lower BMD than controls. For TCS receiving more than two cycles chemotherapy, there was a borderline statistically significant decrease in hip BMD, but this association was not robust for adjustment for hypogonadism. The literature on BMD in relation to TGC and its treatment is relatively scarce. Recently Willemse et al. (2014) reported significant decrease in spine and hip BMD one year after chemotherapy, but no relation to gonadal status of the men. However, this study was based on a slightly smaller number of patients, no controls were included and the association between treatment and BMD was not adjusted for hypogonadism. Another study, (Murugaesu et al., 2009 ) based on 39 TCS, found no increased risk of osteoporosis after a follow-up of 5-28 years. No separate assessment for those having testosterone deficiency was done, why the general conclusion of the study is in agreement with our findings for the total group of TCS and also with an earlier report (Stutz et al., 1998) including 30 stage I seminoma patients. Another study of 125 TCS presenting with testosterone levels within normal range (Foresta et al., 2013) , found an increase in proportion of men with low bone density (Z-score below À2) as compared with controls. Although this finding might seem to be contradictory to our findings, one should keep in mind that in Foresta et al., the patient group had significantly higher LH levels than controls, indicating that some of them were truly hypogonadal. We have included high LH as one of the criteria for defining hypogonadism. Finally, in a recently published study on 1249 testicular cancer survivors examined on average 7 years after treatment, Ondrusova et al. found 43-51% of testicular cancer survivors treated with unilateral orchidectomy alone or in combination with radiotherapy/2-4 cycles of chemotherapy presenting with osteopoenia or osteoporosis (T-/Z-score <À1). There was no increased risk of osteopoenia/osteoporosis between the different treatment groups. Both low testosterone and high LH were more often seen in TCS with low BMD compared to those with normal BMD. However, BMD in eugonadal vs. hypogonadal TCS was not compared (Ondrusova et al., 2016) .
Hypogonadism was more prevalent among TCS than among controls in our study. A recent meta-analysis reported statistically increased risk of testosterone deficiency in TCS treated with orchidectomy plus ≤4 cycles of cisplatin-based chemotherapy, infradiaphragmatic radiotherapy or more extensive treatment, compared to TCS treated with orchidectomy alone (Bandak et al., 2016) . In vitro studies have shown that cisplatin impairs Leydig cell function in a dose dependent manner, this effect being mediated through increased production of reactive oxygen species (Garcia et al., 2012) . It therefore seems plausible that the increased prevalence of hypogonadism in our TCS cohort resulted from previous testicular cancer treatment.
The finding of decreased BMD and increased OR for low BMD in hypogonadal men is biologically plausible. Oestradiol, an important regulator of BMD (Cauley, 2015) is a testosterone metabolite, thus, androgen deficiency leads to a decreased oestrogenic activity. Interestingly, in our study even men on androgen replacement presented with decreased BMD, although their risk of osteopoenia was not increased. In TGC men, testicular function is decreased even prior to cancer diagnosis. Thus, it cannot be excluded that the negative impact of long standing hypogonadism on BMD was not fully compensated by some years of testosterone treatment.
We found no impact of the irradiation of the retroperitoneal lymph nodes on the lower spine or total hip bone density. Previous studies indicated that chemotherapy per se might have a negative impact on bone mineralization (Paccou et al., 2014) . We found a borderline statistically significantly lower BMD in those TCS who received three or more cycles of chemotherapy. 902 Andrology, 2017, 5, 898-904 This association seemed to disappear after adjustment for hypogonadism. However, it should be kept in mind that the group of men treated with more than four chemotherapy cycles included five patients only, which gives our calculations low power.
A weakness of our study is low number of men being on androgen replacement and lack of data on duration of androgen replacement therapy. Such information would give some indications about the long term impact of testosterone therapy on BMD of TCS. An additional limitation is, apart from smoking, the lack of information regarding lifestyle factors, such as physical activity. Low participation rate among the controls might also lead to selection bias, but our register data on the number of children among participants and non-participants do not indicate selection of controls due to impairment of reproductive function. Furthermore, the within patient group comparisons as hypogonadal vs. eugonadal, are not dependent on selection of controls.
The study has also some obvious strengths. Inclusion of age matched controls allowed us to draw more valid conclusions as considers the bone status of TCS in relation to that in the general population. The size of our patient cohort made it possible to discriminate between different treatment modalities and also to compare eugonadal and hypogonadal men. The diagnosis of hypogonadism was based on hormone values measured in blood samples obtained under standardized and proper conditionsfasting, before 10 am. Although only 91 of the original cohort of 165 TCS were included in the study, the distribution between those having children and childless men was similar in participants and the remaining eligible patients, which indicated reduced risk of selection bias related to reproductive function.
Our results have some important clinical implications. A significant proportion of TCS are hypogonadal and are, therefore, at increased risk of having secondarily reduced bone density. Taking into consideration the relatively young age of these patients, and also age related decline in testosterone levels, BMD assessment and, if necessary, preventive measures should be a part of routine management of TCS with low testosterone levels and/or increased LH. In choosing the strategy for prevention of osteoporosis, the full range of possible interventions should be considered. Regarding the effect of testosterone treatment on BMD, two meta-analyses of randomized controlled trials found a modest but significant improvement on lumbar spine BMD, but non-significant effect on femoral neck BMD (Isidori et al., 2005; Tracz et al., 2006) . Both meta-analysis included patients generally older than our study population, and included patients with hypogonadism or low normal testosterone at start of testosterone treatment.
In conclusion, although no significant decrease in BMD was seen in the entire group of TGC survivors, those presenting with hypogonadism -representing a significant proportion of this patient group -are at increased risk of impaired bone health. Prevention of osteoporosis should be considered as an important part in future follow up of TCS.
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